Cullen Frost Bankers Inc. increased its stake in shares of Stryker Co. (NYSE:SYK) by 3.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,750 shares of the medical technology company’s stock after buying an additional 568 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Stryker were worth $3,727,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of SYK. Evolution Wealth Advisors LLC acquired a new stake in Stryker during the fourth quarter worth approximately $33,000. Garrett Wealth Advisory Group LLC acquired a new stake in Stryker during the third quarter worth approximately $35,000. Hudock Capital Group LLC grew its position in Stryker by 123.5% during the fourth quarter. Hudock Capital Group LLC now owns 181 shares of the medical technology company’s stock worth $38,000 after buying an additional 100 shares in the last quarter. Evoke Wealth LLC acquired a new stake in Stryker during the third quarter worth approximately $42,000. Finally, Horan Capital Advisors LLC. acquired a new stake in Stryker during the third quarter worth approximately $43,000. 73.29% of the stock is currently owned by institutional investors and hedge funds.
In other news, COO Timothy J. Scannell sold 4,666 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $206.28, for a total value of $962,502.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by corporate insiders.
Shares of SYK stock opened at $221.54 on Friday. Stryker Co. has a fifty-two week low of $174.84 and a fifty-two week high of $223.45. The company has a market cap of $81.44 billion, a PE ratio of 26.32, a P/E/G ratio of 2.40 and a beta of 0.74. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.84 and a current ratio of 2.58. The stock’s fifty day moving average price is $212.31 and its two-hundred day moving average price is $211.89.
Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $2.49 EPS for the quarter, beating the Zacks’ consensus estimate of $2.46 by $0.03. Stryker had a return on equity of 25.75% and a net margin of 13.99%. The company had revenue of $4.13 billion during the quarter, compared to analysts’ expectations of $4.11 billion. During the same period in the prior year, the company earned $2.18 EPS. Stryker’s revenue was up 8.8% compared to the same quarter last year. On average, equities analysts predict that Stryker Co. will post 9.1 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.575 dividend. This represents a $2.30 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Monday, March 30th. Stryker’s payout ratio is 27.85%.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.